Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Income from Continuing Operations: 2010-2024

Historic Income from Continuing Operations for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$74.3 million.

  • Northwest Biotherapeutics' Income from Continuing Operations fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
  • As of FY2024, Northwest Biotherapeutics' Income from Continuing Operations stood at -$74.3 million, which was down 22.27% from -$60.7 million recorded in FY2023.
  • Northwest Biotherapeutics' Income from Continuing Operations' 5-year high stood at -$57.7 million during FY2021, with a 5-year trough of -$95.1 million in FY2020.
  • In the last 3 years, Northwest Biotherapeutics' Income from Continuing Operations had a median value of -$73.2 million in 2022 and averaged -$69.4 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Income from Continuing Operations crashed by 207.39% in 2020, and later soared by 39.34% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' Income from Continuing Operations (Yearly) stood at -$95.1 million in 2020, then skyrocketed by 39.34% to -$57.7 million in 2021, then decreased by 26.92% to -$73.2 million in 2022, then grew by 17.07% to -$60.7 million in 2023, then dropped by 22.27% to -$74.3 million in 2024.